Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 4;15(6):1750–1761. doi: 10.7150/jca.91089

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Inhibition of EGFR significantly decreased B7-H3-induced chemoresistance to OXP in vivo. A. The schema of gefitinib and OXP treatment. CT26-Vec. and CT26-B7-H3 cells were subcutaneous injected into BALB/c nude mice for 7 days. OXP (5 mg/kg), gefitinib (50 mg/kg) and anti-B7-H3 antibodies (100 μg/ mouse) were given on indicated days (n=5/group). Tumor volume was recorded every three days. Two-Way ANOVA analysis. *p<0.05 and **p<0.01. B. The resected tumor tissues were analyzed by IHC to examine the percentage of apoptotic cells (TUNEL⁺ cells and cleaved caspase-3). One-Way ANOVA analysis. *p<0.05. C. The percentage of apoptotic cells (TUNEL⁺ cells) was quantified (n=3). One-Way ANOVA analysis. *p<0.05, **p<0.01 and ***p<0.001. D. The percentage of cleaved caspase-3-positive cells was quantified (n=3). One-Way ANOVA analysis. *p<0.05, **p<0.01 and ***p<0.001.